Literature DB >> 10479277

Probing the binding of indolactam-V to protein kinase C through site-directed mutagenesis and computational docking simulations.

S Wang1, M Liu, N E Lewin, P S Lorenzo, D Bhattacharrya, L Qiao, A P Kozikowski, P M Blumberg.   

Abstract

Protein kinase C (PKC) comprises a family of ubiquitous enzymes transducing signals by the lipophilic second messenger sn-1, 2-diacylglycerol (DAG). Teleocidin and its structurally simpler congener indolactam-V (ILV) bind to PKC with high affinity. In this paper, we report our computational docking studies on ILV binding to PKC using an automatic docking computer program, MCDOCK. In addition, we used site-directed mutagenesis to assess the quantitative contribution of crucial residues around the binding site of PKC to the binding affinity of ILV to PKC. On the basis of the docking studies, ILV binds to PKC in its cis-twist conformation and forms a number of optimal hydrogen bond interactions. In addition, the hydrophobic groups in ILV form "specific" hydrophobic interactions with side chains of a number of conserved hydrophobic residues in PKC. The predicted binding mode for ILV is entirely consistent with known structure-activity relationships and with our mutational analysis. Our mutational analysis establishes the quantitative contributions of a number of conserved residues to the binding of PKC to ILV. Taken together, our computational docking simulations and analysis by site-directed mutagenesis provide a clear understanding of the interaction between ILV and PKC and the structural basis for design of novel, high-affinity, and isozyme-selective PKC ligands.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10479277     DOI: 10.1021/jm990129n

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  1 in total

Review 1.  Structural insights into C1-ligand interactions: Filling the gaps by in silico methods.

Authors:  Sachin Katti; Tatyana I Igumenova
Journal:  Adv Biol Regul       Date:  2021-01-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.